Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

TY - JOUR

T1 - Expert consensus document

T2 - Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

AU - Banales, Jesus M

AU - Cardinale, Vincenzo

AU - Carpino, Guido

AU - Marzioni, Marco

AU - Andersen, Jesper B

AU - Invernizzi, Pietro

AU - Lind, Guro E

AU - Folseraas, Trine

AU - Forbes, Stuart J

AU - Fouassier, Laura

AU - Geier, Andreas

AU - Calvisi, Diego F

AU - Mertens, Joachim C

AU - Trauner, Michael

AU - Benedetti, Antonio

AU - Maroni, Luca

AU - Vaquero, Javier

AU - Macias, Rocio I R

AU - Raggi, Chiara

AU - Perugorria, Maria J

AU - Gaudio, Eugenio

AU - Boberg, Kirsten M

AU - Marin, Jose J G

AU - Alvaro, Domenico

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.

AB - Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.

U2 - 10.1038/nrgastro.2016.51

DO - 10.1038/nrgastro.2016.51

M3 - Journal article

SN - 1759-5045

VL - 13

SP - 261

EP - 280

JO - Nature Reviews. Gastroenterology & Hepatology

JF - Nature Reviews. Gastroenterology & Hepatology

IS - 5

ER -